2022年07月05日,香港中文大学蓝辉耀教授、中山大学孙逸仙纪念医院徐安平教授课题组合作在Molecular Therapy上发表题为“P2Y12 inhibitor, Clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition”的研究。该研究首...
However, during the last decade the P2Y12-inhibitor clopidogrel has accompanied aspirin to further improve clinical outcomes. P2Y12-inhibitors are antiplatelet agents preventing the binding of adenosine diphosphate to P2Y12-receptors on the platelet surface thus inhibiting platelet aggregation.Recently, the...
This latest registry analysis, however, suggests early administration of these drugs still has a role to play. “We found that the benefits are time dependent, and we found that the benefit in a reduction of a MACE consists of all-cause mortality, myocardial infection, stroke, and definite st...
All patients were recommended to take aspirin and a P2Y12 inhibitor at least for 12 months after index procedure unless there was an undisputed reason for discontinuing antiplatelet agents. Medications including beta-blockers, renin–angiotensin–aldosterone system inhibitors, statins, and oral ...
Proton pump inhibitor 9557 (30.6%) 4442 (27.7%) 4789 (34.0%) 326 (29.2%) −24.5 −15.4 AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; NSTEMI, non-ST-elevated myocardial infarction; PCI, percutaneous ...
The efficacy and safety of P2Y12 inhibitors (P2Y12i) with aspirin in patients with non-cardioembolic ischemic cerebrovascular events remains a topic of ongoing debate. Therefore, we conducted an updated meta-analysis to compare these drugs with aspirin alone. Methods We systematically searched PubMed...
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 year
All patients were recommended to take aspirin and a P2Y12 inhibitor at least for 12 months after index procedure unless there was an undisputed reason for discontinuing antiplatelet agents. Medications including beta-blockers, renin–angiotensin–aldosterone system inhibitors, statins, and oral ...
Clopidogrel, a P2Y12 inhibitor, is a novel anti-fibrosis agent for chronic kidney disease (CKD), but its mechanisms remain unclear, which we investigated by silencing P2Y12 or treating unilateral ureteral obstruction (UUO) in LysM-Cre/Rosa Tomato mice with clopidogrel in vivo and in vitro. We...
Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial[J]. JAMA, 2019,321(24):2428-2437. DOI: 10.1001/jama.2019.8146 . 返回引文位置Google Scholar 百度学术 万方...